retatrutide phase 2 nejm 2023 obesity trial results Availability & Timeline 🤔 Adults with type 2

Breguet, V., Gugerli, R., von Stockar, U

This shorter duration of action makes IGF-1 DES more suitable for research needing acute, localized effects or where rapid clearance is desired

d , Cell death- i nducing DFFA-like effector a (Cidea1)

However, recent observations and clinical studies have raised concerns regarding the potential association between GLP-1 RA use and the risk of pancreatic cancer [1,2]

Your body needs time to adapt, and giving it the right support whether through better eating habits, proper rest, or professional guidance ensures you can keep progressing without compromising your well-being